Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $59.3 million.

  • Puma Biotechnology's Non-Current Assets fell 7.23% to $59.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.3 million, marking a year-over-year decrease of 7.23%. This contributed to the annual value of $65.7 million for FY2024, which is 11.66% down from last year.
  • Latest data reveals that Puma Biotechnology reported Non-Current Assets of $59.3 million as of Q3 2025, which was up 1.62% from $58.3 million recorded in Q2 2025.
  • Puma Biotechnology's Non-Current Assets' 5-year high stood at $94.9 million during Q1 2021, with a 5-year trough of $58.3 million in Q2 2025.
  • Over the past 3 years, Puma Biotechnology's median Non-Current Assets value was $67.3 million (recorded in 2024), while the average stood at $69.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 41.95% in 2021, then declined by 18.33% in 2024.
  • Over the past 5 years, Puma Biotechnology's Non-Current Assets (Quarterly) stood at $86.6 million in 2021, then rose by 1.40% to $87.8 million in 2022, then declined by 15.31% to $74.3 million in 2023, then fell by 11.66% to $65.7 million in 2024, then dropped by 7.23% to $59.3 million in 2025.
  • Its last three reported values are $59.3 million in Q3 2025, $58.3 million for Q2 2025, and $63.7 million during Q1 2025.